Impact of Intrauterine Infusion of Autologous Platelet-Rich Plasma on Assisted Reproductive Outcomes in Patients With Recurrent Implantation Failure: A Meta-Analysis of Randomized Controlled Trials.

BACKGROUND

This meta-analysis evaluates the efficacy and safety of intrauterine autologous platelet-rich plasma (PRP) infusion in patients with recurrent implantation failure (RIF).

METHODS

Following PRISMA guidelines, we systematically searched major databases and included 10 randomized controlled trials (RCTs, n = 1 188). Study quality was assessed using the Cochrane RoB 2.0 tool.

RESULTS

PRP infusion significantly improved clinical pregnancy rate (RR = 2.23, 95% CI 1.84-2.69) and live birth rate (RR = 3.74, 95% CI 2.68-5.22) without increasing miscarriage risk. Subgroup analysis indicated that a 0.5 mL PRP volume was as effective as 0.5-1.0 mL, and a notably greater treatment effect was observed in blastocyst transfer cycles compared to cleavage-stage embryo transfers, suggesting potential enhanced benefit in this subgroup.

CONCLUSION

Intrauterine PRP infusion is an effective and safe treatment for RIF. The findings on dose equivalence and differential efficacy by embryo stage offer valuable insights for optimizing clinical application.